From: Tumor-associated myeloid cells in cancer immunotherapy
TAMCs | Contents | Technologies |
---|---|---|
TAM | Origin | Ms4a3TdT, Ms4a3Cre, Ms4a3CreERT2 mouse models to specifically dissect monocyte-differentiation pathways |
Biomarkers | F4/80, CD11b, CD86, CD206, etc | |
Chemotaxis | Anti-CCL2 antibody, CCL5-KO mouse, etc., used to block TAM recruitment | |
Regulation | Anti-M-CSF antibody, anti-CSF-1R antibody, etc., used to interfere with TAM differentiation | |
Function | Liposomal clodronate, CD11b-DTR mouse, etc., used to verify the effect of TAM clearance | |
MDSC | Origin | Splenectomy is performed to determine the origin of splenic MDSC |
Biomarkers | CD11b, CD14, CD15, CD66b, HLA-DR (human) and CD11b, Ly6G, Ly6C (mouse), etc | |
Chemotaxis | CXCR2 blockade, CXCR4 blockade, etc., used to inhibit MDSC recruitment | |
Regulation | GM-CSF overexpression cell line (e.g. B16-GM), anti-GM-CSF antibody, etc., used to explore the factors regulating MDSC differentiation | |
Function | (a) Anti-Gr-1 antibody, etc., used to consume MDSC (b) DR5 agonist, LXR agonist, etc., used to induce apoptosis of MDSC | |
TAN | Origin | Label by mNPPFC (mNP specifically bind to CD177) to follow TAN |
Biomarkers | CD15, CD16, CD66b, CD14, HLA-DR (human) and CD11b, Ly6G (mouse), etc | |
Chemotaxis | CXCR2 blockade, etc., used to inhibit TAN recruitment | |
Regulation | Anti-TGF-βantibody, anti-IFN-γantibody, etc., used to explore the regulation of TAN polarization | |
Function | (a) Clear by anti-Ly6G antibody (b) Induce by G-CSF | |
TADC | Origin | Zbtb46-GFP mouse to track TADC |
Biomarkers | BDCA-1, BDCA-2, BDCA-3, BDCA-4, CD141, CD1c, CD11c, IL-3Ra, CD45R, CD317, Siglec-H, etc | |
Chemotaxis | Anti-CCL5 antibody, anti-CXCL12 antibody, etc., used to block TADC recruitment | |
Regulation | Anti-TGF-β antibody, anti-TPO antibody, etc., used to explore the factors regulating TADC differentiation | |
Function | CD11c-DTR mouse, Zbtb46-2A-CreERT2 mouse, etc., used to conditionally remove TADC |